Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
Kort samengevat
Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed...
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Insider Monkey.
Lees het volledige bericht ↗